Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

Akari Therapeutics logo
$1.00 -0.03 (-3.20%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$1.45 +0.45 (+45.44%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Key Stats

Today's Range
$0.97
$1.02
50-Day Range
$1.00
$1.42
52-Week Range
$0.85
$4.22
Volume
5,511 shs
Average Volume
28,831 shs
Market Capitalization
$32.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Akari Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

AKTX MarketRank™: 

Akari Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 666th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akari Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Akari Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.13% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently decreased by 8.02%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Akari Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akari Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently decreased by 8.02%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,120.00 in company stock and sold $0.00 in company stock.

    • Percentage Held by Insiders

      38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 5.06% of the stock of Akari Therapeutics is held by institutions.

    • Read more about Akari Therapeutics' insider trading history.
    Receive AKTX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    AKTX Stock News Headlines

    Crypto bros: Meet your replacement
    Larry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.
    See More Headlines

    AKTX Stock Analysis - Frequently Asked Questions

    Akari Therapeutics' stock was trading at $1.22 on January 1st, 2025. Since then, AKTX shares have decreased by 18.3% and is now trading at $0.9970.

    Akari Therapeutics PLC (NASDAQ:AKTX) issued its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

    Akari Therapeutics's stock reverse split before market open on Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Top institutional investors of Akari Therapeutics include Omnia Family Wealth LLC (0.19%).
    View institutional ownership trends
    .

    Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

    Company Calendar

    Last Earnings
    3/31/2020
    Today
    8/06/2025
    Next Earnings (Estimated)
    8/18/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:AKTX
    CIK
    1541157
    Employees
    9
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $5.00
    Low Price Target
    $5.00
    Potential Upside/Downside
    +401.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$19.79 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -213.59%
    Return on Assets
    -65.60%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.16
    Quick Ratio
    0.16

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.84 per share
    Price / Book
    1.19

    Miscellaneous

    Outstanding Shares
    32,180,000
    Free Float
    19,917,000
    Market Cap
    $32.08 million
    Optionable
    Not Optionable
    Beta
    0.22
    Reduce the Risk Cover

    Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

    Get This Free Report

    This page (NASDAQ:AKTX) was last updated on 8/6/2025 by MarketBeat.com Staff
    From Our Partners